These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 141327)

  • 21. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
    Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
    Chemioterapia; 1988 Oct; 7(5):345-9. PubMed ID: 3224403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of advanced breast cancer with alkylating agents].
    Pipino G; Germiniani R; Lavorato F; Tajana A
    Minerva Med; 1977 Mar; 68(13):823-30. PubMed ID: 403484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
    Ostrow S; Egorin M; Aisner J; Bachur N; Wiernik PH
    Cancer Clin Trials; 1980; 3(1):23-7. PubMed ID: 7190082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical evaluation of estramustine phosphate in the treatment of patients with advanced breast cancers].
    Wada T; Morikawa E; Houjou T; Kadota K; Mori N; Matsunami N; Watatani M; Yasutomi M
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1901-4. PubMed ID: 2393306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
    Harris AL; Powles TJ; Smith IE
    Cancer Res; 1982 Aug; 42(8 Suppl):3405s-3408s. PubMed ID: 7083207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma.
    Tormey DC; Simon R; Falkson G; Bull J; Band P; Perlin E; Blom J
    Cancer Res; 1977 Feb; 37(2):529-34. PubMed ID: 832277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of cytembena in patients with advanced ovarian and breast cancer.
    Falkson HC; Falkson G
    Cancer Treat Rep; 1976 Nov; 60(11):1655-8. PubMed ID: 1037286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.
    Fornasiero A; Daniele O; Fosser VP; Paccagnella A; Salvagno L; Sileni VC; Morandi P; Fiorentino MV
    Cancer Treat Rep; 1986 May; 70(5):647-9. PubMed ID: 3708613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.
    Yap HY; Blumenschein GR; Bodey GP; Hortobagyi GN; Buzdar AU; DiStefano A
    Cancer Treat Rep; 1981; 65(9-10):775-9. PubMed ID: 7273012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
    Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
    Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical trial of lentaron for postmenopausal patients with advanced breast cancer].
    Liu X; Song S; Jiang Z; Wu S; Yu J; Wang T
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):511-3. PubMed ID: 12485513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.
    Pannuti F; Martoni A; Lenaz GR; Piana E; Nanni P
    Cancer Treat Rep; 1978 Apr; 62(4):499-504. PubMed ID: 350387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
    Chang YC; Falkson G; Tormey DC; Crowley J
    Cancer Clin Trials; 1981; 4(4):377-80. PubMed ID: 6797746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 7beta,17alpha-Dimethyltestosterone (calusterone)-induced changes in the metabolism, production rate, and excretion of estrogens in women with breast cancer: a possible mechanism of action.
    Fishman J; Hellman L
    J Clin Endocrinol Metab; 1976 Feb; 42(2):365-9. PubMed ID: 131130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer.
    Lloyd RE; Jones SE; Salmon SE
    Cancer; 1979 Jan; 43(1):60-5. PubMed ID: 153787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calusterone in the therapy for advanced breast cancer.
    Gordan GS; Wessler S; Avioli LV
    JAMA; 1972 Jan; 219(4):483-90. PubMed ID: 5066641
    [No Abstract]   [Full Text] [Related]  

  • 40. Calusterone (7beta,17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer.
    Gordan GS; Halden A; Horn Y; Fuery JJ; Parsons RJ; Walter RM
    Oncology; 1973; 28(2):138-46. PubMed ID: 4583006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.